Literature DB >> 18544995

Identification of genes targeted by CpG island methylator phenotype in neuroblastomas, and their possible integrative involvement in poor prognosis.

Masanobu Abe1, Naoko Watanabe, Nathalie McDonell, Tsuyoshi Takato, Miki Ohira, Akira Nakagawara, Toshikazu Ushijima.   

Abstract

BACKGROUND/AIMS: CpG island (CGI) methylator phenotype (CIMP) is strongly associated with poor prognosis in neuroblastomas (NBLs; hazard ratios 7-22). Methylation of nonpromoter CGIs is useful to detect the presence of the CIMP, while the poor prognosis is considered to be caused by gene silencing due to promoter methylation. Here, promoter CGIs targeted by the CIMP were searched for.
METHODS: A genome-wide screening was performed by methylation-sensitive representational difference analysis of CIMP(+) and CIMP(-) NBLs.
RESULTS: Promoter CGIs of 9 genes were methylated in CIMP(+) NBL cell lines and caused silencing of their downstream genes. On analysis of 90 clinical specimens, CYP26C1,FERD3L (N-TWIST), CRYBA2 and PCDHGC4 were methylated at significantly higher incidences in CIMP(+) NBLs than CIMP(-) NBLs, while the difference was unclear for NPY, SPAG6, DDIT4L, CHR3SYT and C6Orf141. Methylation of CYP26C1 and FERD3L was significantly associated with poor prognosis, but weaker than the presence of the CIMP. Treatment of an NBL cell line with a demethylating agent caused demethylation of multiple promoter CGIs, and enhanced 13-cis-retinoic acid-induced neuronal differentiation.
CONCLUSION: Our results indicate that the CIMP causes poor prognosis of NBLs by inducing methylation of multiple promoter CGIs with various incidences. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 18544995     DOI: 10.1159/000139124

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  29 in total

Review 1.  New aspects of neuroblastoma treatment: ASPHO 2011 symposium review.

Authors:  Peter E Zage; Chrystal U Louis; Susan L Cohn
Journal:  Pediatr Blood Cancer       Date:  2012-02-29       Impact factor: 3.167

2.  CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis.

Authors:  Tao Fu; Emmanouil P Pappou; Angela A Guzzetta; Jana Jeschke; Ruby Kwak; Pujan Dave; Craig M Hooker; Richard Morgan; Stephen B Baylin; Christine A Iacobuzio-Donahue; Christopher L Wolfgang; Nita Ahuja
Journal:  Clin Cancer Res       Date:  2012-07-23       Impact factor: 12.531

3.  Phase I study of tamibarotene monotherapy in pediatric and young adult patients with recurrent/refractory solid tumors.

Authors:  Chika Nitani; Junichi Hara; Hiroshi Kawamoto; Tomoaki Taguchi; Toshimi Kimura; Kenichi Yoshimura; Akinobu Hamada; Shigehisa Kitano; Naoko Hattori; Toshikazu Ushijima; Hiromi Ono; Masako Nakamoto; Tsukiko Higuchi; Akihiro Sato
Journal:  Cancer Chemother Pharmacol       Date:  2021-04-07       Impact factor: 3.333

4.  Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma.

Authors:  María Berdasco; Santiago Ropero; Fernando Setien; Mario F Fraga; Pablo Lapunzina; Régine Losson; Miguel Alaminos; Nai-Kong Cheung; Nazneen Rahman; Manel Esteller
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

5.  Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines.

Authors:  Qiwei Yang; Yufeng Tian; Kelly R Ostler; Alexandre Chlenski; Lisa J Guerrero; Helen R Salwen; Lucy A Godley; Susan L Cohn
Journal:  BMC Cancer       Date:  2010-06-14       Impact factor: 4.430

6.  Identification of novel methylation markers in hepatocellular carcinoma using a methylation array.

Authors:  So Hyun Shin; Baek-hui Kim; Ja-June Jang; Kyung Suk Suh; Gyeong Hoon Kang
Journal:  J Korean Med Sci       Date:  2010-07-20       Impact factor: 2.153

7.  A six-CpG panel with DNA methylation biomarkers predicting treatment response of chemoradiation in esophageal squamous cell carcinoma.

Authors:  Wei-Lun Chang; Wu-Wei Lai; I-Ying Kuo; Chien-Yu Lin; Pei-Jung Lu; Bor-Shyang Sheu; Yi-Ching Wang
Journal:  J Gastroenterol       Date:  2016-09-26       Impact factor: 7.527

8.  Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype.

Authors:  Priyanka Kanth; Mary P Bronner; Kenneth M Boucher; Randall W Burt; Deborah W Neklason; Curt H Hagedorn; Don A Delker
Journal:  Cancer Prev Res (Phila)       Date:  2016-03-29

9.  Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.

Authors:  Ziyan Lu; Yufeng Tian; Helen R Salwen; Alexandre Chlenski; Lucy A Godley; J Usha Raj; Qiwei Yang
Journal:  Anticancer Drugs       Date:  2013-06       Impact factor: 2.248

10.  Development of a novel output value for quantitative assessment in methylated DNA immunoprecipitation-CpG island microarray analysis.

Authors:  Satoshi Yamashita; Kosuke Hosoya; Ken Gyobu; Hideyuki Takeshima; Toshikazu Ushijima
Journal:  DNA Res       Date:  2009-09-18       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.